CorMedix Inc. (NYSE: CRMD) disclosed that its Professor of Medicine and Director of Nephrology, would deliver a oral presentation. The title was "A Novel Taurolidine Containing Catheter Lock Solution CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study."
CorMedix said that the data would be presented at the 53rd ERA-EDTA congress that is being held in May in Austria between 21 and 24.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The company's CEO, Randy Milby, commented, "The Neutrolin Usage Monitoring Program data has produced valuable insights from real world use in the EU, where Neutrolin is approved for the reduction of catheter-related blood stream infections and thrombosis."
He said further, "We've shared some general data from the program, which has demonstrated positive results consistent with our trials that appear to validate Neutrolin's clinical utility. We look forward to presenting a more formal analysis to this esteemed gathering of nephrologists."